EpimAb Biotherapeutics

Focus: EpimAb Biotherapeutics is a Shanghai-based oncology-focused biotech specializing in bi-specific antibody therapeutics. The company is early-stage with a pipeline of 7 active clinical trials across Phase 1/2 programs.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About EpimAb Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow EpimAb Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EMB-09

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05263180A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Phase 1

Help build intelligence for EpimAb Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in bi-specific antibodies, an emerging modality with significant commercial potential in oncology
Diverse oncology pipeline with 9 programs across lung cancer, solid tumors, multiple myeloma, and colorectal cancer
Ground-floor opportunity to shape clinical development and manufacturing at a focused, specialized biotech

Watch Out For

No active job postings and limited hiring visibility suggest constrained near-term growth or belt-tightening
Early-stage pipeline with no Phase 3 programs or approved products—extended runway to revenue and inherent clinical/commercial risk
China headquarters may complicate regulatory strategy, IP enforcement, and talent acquisition in Western markets

Generated by Claude from EpimAb Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EMB07

Advanced/Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT05607498First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Phase 1

EMB07

Combination Therapy

Phase 1/2

Clinical Trials (1)

NCT07432022A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 1/2

EMB-06

Relapsed or Refractory Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT04735575A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Phase 1/2

EMB-02

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT04618393A Study of EMB-02 in Participants With Advanced Solid Tumors